by Mark Vanelli, MD, MHS, Susan Adler, and Jim Vermilyea, PhD
Direct-to-consumer (DTC) advertising of pharmaceuticals is both big and relatively new. Since the FDA in 1997 allowed drug companies to...
While DTC ads work when the end consumer is an able judge of product performance, as with medications for seasonal allergies, sexual dysfunction, or hair loss, they don't work nearly as well for asymptomatic illnesses. For these conditions, DTC may help increase patient acquisition and trial, but often fails to improve long-term use, thus under-performing both clinical expectations for patients and financial expectations for manufacturers. Optimal DTC programs should integrate patient acquisition strategies with direct-to-patient support strategies such as, disease-state web sites, refill reminder programs, and financial incentives able to drive ongoing product use.
by Mark Vanelli, MD, MHS, Susan Adler, and Jim Vermilyea, PhD
Direct-to-consumer (DTC) advertising of pharmaceuticals is both big and relatively new. Since the FDA in 1997 allowed drug companies to...
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.